• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Computershare Ltd ADR
Majestic Gold Corp
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1117
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD ↗
January 06, 2024
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
Via Benzinga
News headline image
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗
October 29, 2023
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property

Performance

More News

Read More
News headline image
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents ↗
October 26, 2023
Via Benzinga
Topics Intellectual Property
News headline image
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics ↗
October 23, 2023
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
October 23, 2023
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗
October 22, 2023
Via Benzinga
News headline image
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business ↗
October 20, 2023
Via Benzinga
News headline image
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
October 19, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement ↗
October 18, 2023
Via Benzinga
News headline image
Small Pharma Obtains Final Order Approving Arrangement
October 17, 2023
From Cybin Inc.
Via Business Wire
News headline image
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗
October 16, 2023
Via Benzinga
News headline image
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates ↗
October 13, 2023
Via Benzinga
News headline image
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
October 12, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗
October 02, 2023
Via Benzinga
News headline image
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results ↗
September 26, 2023
Via Benzinga
News headline image
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗
September 26, 2023
Via Benzinga
Topics Economy
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 26, 2023
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression ↗
September 21, 2023
Via Benzinga
News headline image
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update ↗
September 18, 2023
Via Benzinga
News headline image
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT ↗
September 05, 2023
Via Benzinga
Topics Intellectual Property
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
September 05, 2023
Via Benzinga
News headline image
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗
August 31, 2023
Via Benzinga
News headline image
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M ↗
August 29, 2023
Via Benzinga
News headline image
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety ↗
August 28, 2023
Via Benzinga

Frequently Asked Questions

Is Small Pharma Inc publicly traded?
Yes, Small Pharma Inc is publicly traded.
What exchange does Small Pharma Inc trade on?
Small Pharma Inc trades on the OTC Traded
What is the ticker symbol for Small Pharma Inc?
The ticker symbol for Small Pharma Inc is DMTTF on the OTC Traded
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap